The National Forum for Heart Disease & Stroke Prevention is pleased that the U.S. Food and Drug Administration (FDA) approved Repatha™ (evolocumab), the second PCSK9 inhibitor to enter the market this year. This newly available therapy will serve to markedly reduce low density lipoprotein cholesterol (LDL-C), or “bad cholesterol”, among patients whose elevated LDL-C levels place them at elevated risk for heart attacks and strokes. Repatha has been shown in clinical trials to significantly reduce LDL-C, with minimal side effects, among patients with cholesterol levels that are too high despite previous therapies or who have familial hyperlipidemia, an inherited high cholesterol disorder.
More at National Forum for Heart Disease & Stroke Prevention